Cargando…

A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study

INTRODUCTION: Venous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long‐term morbidity. BACKGROUND: A patient charity developed an information video for patients receiving systemic anticancer therapy incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Baddeley, Elin, Torrens‐Burton, Anna, Newman, Alisha, Nelson, Annmarie, Pease, Nikki, Nelson, Rosie, Noble, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357625/
https://www.ncbi.nlm.nih.gov/pubmed/34401640
http://dx.doi.org/10.1002/rth2.12545
_version_ 1783737169904402432
author Baddeley, Elin
Torrens‐Burton, Anna
Newman, Alisha
Nelson, Annmarie
Pease, Nikki
Nelson, Rosie
Noble, Simon
author_facet Baddeley, Elin
Torrens‐Burton, Anna
Newman, Alisha
Nelson, Annmarie
Pease, Nikki
Nelson, Rosie
Noble, Simon
author_sort Baddeley, Elin
collection PubMed
description INTRODUCTION: Venous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long‐term morbidity. BACKGROUND: A patient charity developed an information video for patients receiving systemic anticancer therapy including what to do if they developed symptoms of VTE. This was introduced into clinical practice in a regional cancer center and its impact compared with a district general hospital where the video was not used. METHODS: A mixed‐methods approach was used, comprising clinical audit data, patient surveys, and key informant interviews. The time between development of VTE symptoms and seeking medical evaluation was routinely recorded on patients attending a regional cancer‐associated thrombosis service with systemic anticancer therapy–provoked VTE. The video was then embedded into clinical practice at the regional cancer center for 3 months. The primary outcome was the difference in time to presentation with VTE symptoms, between patients attending the regional cancer center and the district general hospital (which acted as control). Other outcomes included impact on radiology resources, patient knowledge, and perspectives of chemotherapy nurses. RESULTS: Addition of the video was associated with a lower mean time to presentation from 8.9 to 2.9 days (0.33 hazard ratio; 95% confidence interval, 4.5‐7.4; P < .0001). This may reflect greater awareness of VTE, resulting in earlier clinical presentation when they developed attributable symptoms. CONCLUSION: The video was associated with reduced delays in diagnosis of systemic anticancer therapy–associated VTE by 6 days, thereby reducing long‐term complications.
format Online
Article
Text
id pubmed-8357625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83576252021-08-15 A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study Baddeley, Elin Torrens‐Burton, Anna Newman, Alisha Nelson, Annmarie Pease, Nikki Nelson, Rosie Noble, Simon Res Pract Thromb Haemost Original Articles INTRODUCTION: Venous thromboembolism (VTE) is a common and serious complication of systemic anticancer therapies. Delays in presentation increase risk of death or long‐term morbidity. BACKGROUND: A patient charity developed an information video for patients receiving systemic anticancer therapy including what to do if they developed symptoms of VTE. This was introduced into clinical practice in a regional cancer center and its impact compared with a district general hospital where the video was not used. METHODS: A mixed‐methods approach was used, comprising clinical audit data, patient surveys, and key informant interviews. The time between development of VTE symptoms and seeking medical evaluation was routinely recorded on patients attending a regional cancer‐associated thrombosis service with systemic anticancer therapy–provoked VTE. The video was then embedded into clinical practice at the regional cancer center for 3 months. The primary outcome was the difference in time to presentation with VTE symptoms, between patients attending the regional cancer center and the district general hospital (which acted as control). Other outcomes included impact on radiology resources, patient knowledge, and perspectives of chemotherapy nurses. RESULTS: Addition of the video was associated with a lower mean time to presentation from 8.9 to 2.9 days (0.33 hazard ratio; 95% confidence interval, 4.5‐7.4; P < .0001). This may reflect greater awareness of VTE, resulting in earlier clinical presentation when they developed attributable symptoms. CONCLUSION: The video was associated with reduced delays in diagnosis of systemic anticancer therapy–associated VTE by 6 days, thereby reducing long‐term complications. John Wiley and Sons Inc. 2021-08-11 /pmc/articles/PMC8357625/ /pubmed/34401640 http://dx.doi.org/10.1002/rth2.12545 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Baddeley, Elin
Torrens‐Burton, Anna
Newman, Alisha
Nelson, Annmarie
Pease, Nikki
Nelson, Rosie
Noble, Simon
A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title_full A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title_fullStr A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title_full_unstemmed A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title_short A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study
title_sort mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: the empower study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357625/
https://www.ncbi.nlm.nih.gov/pubmed/34401640
http://dx.doi.org/10.1002/rth2.12545
work_keys_str_mv AT baddeleyelin amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT torrensburtonanna amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT newmanalisha amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT nelsonannmarie amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT peasenikki amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT nelsonrosie amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT noblesimon amixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT baddeleyelin mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT torrensburtonanna mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT newmanalisha mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT nelsonannmarie mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT peasenikki mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT nelsonrosie mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy
AT noblesimon mixedmethodsstudytoevaluateapatientdesignedtooltoreduceharmfromcancerassociatedthrombosistheempowerstudy